Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma

Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying ways to predict health outcomes in patients who have a type of liver cancer called hepatocellular carcinoma (HCC) along with liver disease but whose liver is still working fairly well. The goal is to see if certain non-invasive tests, like a special scan called transient elastography (which measures liver stiffness) and an examination of the upper digestive tract (called an endoscopy), can help doctors identify risks like serious liver complications or liver-related death over five years after treatment aimed at curing the cancer.

People who might join this study are adults with chronic liver disease and newly diagnosed HCC that can be treated with surgery or local therapies intended to cure the cancer. Those who have had severe liver failure before, previous liver cancer, other types of liver tumors, or major health issues that limit life expectancy are not eligible. If you join, you can expect to have scans and clinical check-ups every six months, plus endoscopies at the start and then at years 1, 3, and 5 after treatment. These tests and visits will help monitor your liver health and catch any problems early. The study is currently recruiting participants and aims to improve how doctors predict and manage liver cancer outcomes in patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 or above
• • Known chronic liver disease(s)
• • HCC for curative-intent treatment (defined by HCC diagnosed with typical radiological features or histology, and planned for surgical resection or local ablative therapy as a curative-intent treatment)
• Exclusion Criteria:
• • Current or history of decompensated liver cirrhosis (i.e. Child's C cirrhosis, prior decompensating events such as ascites, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome)
• • o Child's B cirrhosis without decompensating events is not excluded
• • Past history of HCC (ie. The current HCC is a recurrence of priorly treated HCC or a second de novo HCC after previous first HCC)
• • Non-primary liver tumour (such as secondary liver tumour due to metastasis from another distant primary tumour)
• • History of liver transplantation or plan for liver transplantation as the modality of curative-intent HCC treatment
• • Asplenism or history of splenectomy
• • Contraindication to OGD (eg. Intestinal perforation of obstruction)
• • Serious medical illness with limited life expectancy of less than 6 months
• • Pregnancy
• • Unable to obtain or refusal of informed consent from patient